Results 161 to 170 of about 66,826 (280)

Persistence of advanced therapies in patients with ulcerative colitis: real-world data from the nationwide CREdIT registry. [PDF]

Ther Adv Gastroenterol
Hradsky O, Duricova D, Lukas M, Nedbalová L, Pipek B, Drastich P, Falt P, Vanasek T, Svikova J, Siroky M, Bouchner L, Svoboda P, Bronsky J, Bortlik M.   +13 more
europepmc   +1 more source

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis, Sandra Philipp, Thomas Mosch, Björn Fritz, Robert Sabat   +4 more
wiley   +1 more source

Performance evaluation of an adalimumab biosimilar autoinjector and its reference device: comparative use human factors study in patients with rheumatoid arthritis and juvenile idiopathic arthritis. [PDF]

Drug Deliv
Moses K S, Konda Ramachary Subramanian S.   +1 more
europepmc   +1 more source

Juvenile stroke during long-term therapy with adalimumab. [PDF]

Clinics (Sao Paulo)
Fiorini AC, Scorza FA, Finsterer J, Scorza CA.   +3 more
europepmc   +1 more source

Biologic dose escalation in inflammatory bowel disease in the United States. [PDF]

J Manag Care Spec Pharm
Chapman C, Vadhariya A, Bires N, Brady BL, Creveling T, Ross R, Evans KA, Panni T, Chan-Diehl FW, McGinnis K.   +9 more
europepmc   +1 more source

A tale of two meta-analyses: Similarity, consistency and avoiding overinterpretation in network meta-analysis. [PDF]

J Eur Acad Dermatol Venereol
Shourick J, Garbayo-Salmons P.
europepmc   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, EarlyView.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source

Adalimumab Therapy for Crohn's Disease and Axial Spondyloarthritis in Latent Tuberculosis: <i>A bibliometric-systematic literature review</i>. [PDF]

Sultan Qaboos Univ Med J
Shofa NM, Setiyari Mudjari N, Ekawati R, Arianti A, Zahra Mufida A, Widodo B, Sugihartono T.   +6 more
europepmc   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Adalimumab in the management of refractory idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: a case report and literature review. [PDF]

BMC Ophthalmol
Qadan AB, Zafar MI, Tanveer MA, Berstad BB, Jansson RW.   +4 more
europepmc   +1 more source